Hope for long COVID treatment breakthrough after study’s ‘really positive’ findings

The results of a new study, published in the Lancet eClinical Medicine, showed that an experimental drug (AXA1125) significantly reduces fatigue in people with Long COVID. Scientists who carried out the small-scale clinical trial believe this drug may increase energy production in cells and reduce inflammation for people fighting the virus and its aftereffects.

Hope for long COVID treatment breakthrough after study’s ‚really positive‘ findings | UK News | Sky News

Full article: Efficacy and tolerability of an endogenous metabolic modulator (AXA1125) in fatigue-predominant long COVID: a single-centre, double-blind, randomised controlled phase 2a pilot study – eClinicalMedicine (thelancet.com)